India-based Sun Pharmaceutical Industries Ltdis reportedly evaluating a potential acquisition of Organon & Co (NYSE: OGN ), a U.S.-based women's healthcare company.
If it goes through, the deal that could become the largest cross-border transaction ever by an Indian drugmaker, according to people familiar with the matter, as cited by The Economic Times.
Sun Pharmaceutical has submitted a non-binding all-cash bid and arranged $10–14 billion in acquisition financing.
Why It Matters
If completed, the transaction—valued at about $10 billion including debt—would be Sun Pharma's largest acquisition to date and its most ambitious overseas expansion since the Ranbaxy deal, significantly strengthening its presence in women's health biopharma and biosimilars .
Don't Miss:
-
The AI Marketing Platform Backed by Insiders from Google, Meta, and Amazon — Invest at $0.85/Share
-
Sam Altman Says AI Will Transform the Economy — This Platform Lets Investors Back Private Tech Early
One source described the possible deal as "transformative," saying it would significantly bolster Sun Pharma's presence in the U.S. market, highlighted News18.
People cited by ET said Sun Pharma has engaged a European bank as an adviser, which is preparing a financial proposal for Organon's board. Talks are still at a preliminary stage, and there is no certainty that negotiations will result in a transaction.
Organon was spun off from Merck & Co. (NYSE: MRK ) in 2021 with roughly $9.5 billion in inherited debt. Since then, the company has pursued inorganic growth while attempting to streamline its balance sheet through asset sales.
Another media report added that Sun Pharma has engaged a European bank as an advisor to structure a comprehensive financial proposal.
In September 2024, Organon acquired Dermavant from Roivant Sciences (NASDAQ: ROIV ) for $1.2 billion. More recently, it sold its JADA post-partum hemorrhage system to Laborie Medical for $465 million as part of its divestment of non-core assets.
As of the end of the second quarter of fiscal 2025, Organon's debt stood at $8.9 billion.
Trending: If there was a new fund backed by Jeff Bezos offering a 7-9% target yield with monthly dividends would you invest in it ?
ET reported that Sun Pharma re-engaged in talks after Organon's share price roughly halved, having earlier paused discussions due to valuation concerns. It remains unclear whether Sun Pharma would pursue an all-cash offer or a mix of cash and stock.
People familiar with the matter highlighted that negotiations may not lead to a deal and that a bidding war is also possible. If completed, the combined entity would have pro forma leverage of about 2.5 times net debt to EBITDA.
Organon's Q3 Performance
Organon reported third-quarter adjusted earnings of $1.01 per share, beating the consensus of 94 cents. Sales were up 1% to $1.60 billion, beating the consensus of $1.58 billion .
Organon lowered its fiscal 2025 sales guidance from $6.275 billion-$6.375 billion to $6.20 billion-$6.25 billion, below the consensus of $6.289 billion.
Nexplanon, a contraceptive, is the company's top-selling biopharma product.
Organon's Nexplanon NDA
On Friday, the U.S. Food and Drug Administration (FDA) approved a supplemental New Drug Application for Nexplanon (etonogestrel implant).
The approval extends the duration of use of Nexplanon for up to five years, an extension of the previous three-year indication.
In addition, this approval includes a new Risk Evaluation and Mitigation Strategy (REMS) program in the U.S. to mitigate complications due to improper insertion and removal.
Read Next: From Moxy Hotels to $12B in Real Estate — The Firm Behind NYC's Trendiest Properties Is Letting Individual Investors In.
Photo via Shutterstock
UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily , plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
Get the latest stock analysis from Benzinga:
This article Sun Pharma Eyes Organon In What Could Be India Pharma's Biggest Cross-Border Deal: Report originally appeared on Benzinga.com
